logo
Your body starts aging faster at this ‘inflection point' — it's earlier than you might think

Your body starts aging faster at this ‘inflection point' — it's earlier than you might think

New York Post29-07-2025
Are you over the hill?
A shocking new study has pinpointed the exact window when the human aging process begins to accelerate — and it happens well before you reach senior status.
Researchers found the body breaks down unevenly, with one vital organ taking the hardest hit and possibly speeding up damage elsewhere.
3 Your body's organs aren't aging at the same rate — with one particularly susceptible to early decline.
Vane Nunes – stock.adobe.com
In the study, Chinese scientists analyzed 516 tissue samples from 76 organ donors between the ages of 14 and 68, all of whom died from accidental traumatic brain injury.
The samples covered all of the body's major biological systems, including cardiovascular, digestive, immune, endocrine and skin.
Using advanced analysis, the team found that the number of 48 proteins linked to disease became significantly more prominent as donor age increased.
The proteins were tied to a host of conditions, from cardiovascular disease and tissue fibrosis to fatty liver and liver-related tumors.
But not all organs aged equally. Protein-level changes in the adrenal gland — the hormone-producing powerhouse — began showing up as early as age 30.
But the real shift happened between ages 45 and 55, when protein expression ramped up rapidly across several major organ systems.
3 The body likely hits an 'inflection point' where aging begins to accelerate around the age of 50.
micromonkey – stock.adobe.com
The most dramatic changes showed up in the aorta, the body's main artery responsible for sending oxygen-rich blood from the heart to the rest of the body.
'Temporal analysis revealed an aging inflection around age 50, with blood vessels being a tissue that ages early and is markedly susceptible to aging,' the study authors wrote.
One protein in particular, known as GAS6, stood out. Its levels rose in the aorta as donors got older — and researchers think it may play a central role in triggering aging throughout the body.
In experiments, the team injected young mice with GAS6. After, they found that the rodents developed clear signs of premature aging, including weak grip strength, poor balance and visible damage to their blood vessels.
3 Blood vessels may carry proteins that promote aging throughout the body, researcher suspect.
AJ_stock_photos – stock.adobe.com
'Blood vessels seem to act as a conduit carrying molecules that promote aging throughout the body,' Guanghui Liu, a researcher at the Chinese Academy of Sciences who lead the study, said in an interview with local news outlet The Chosun Daily.
The findings reinforce the growing belief that aging doesn't happen on a straight timeline. However, further research is needed to declare 50 a biological breaking point, according to Maja Olecka, a scientist at the Leibniz Institute on Aging — Fritz Lipmann Institute in Germany, who was not involved in the study.
'There are these waves of age-related changes,' Olecka told Scientific American. 'But it is still difficult to make a general conclusion about the timing of the inflection points.'
In the US, nearly 58 million Americans are 65 and older — and that number is projected to soar to nearly 89 million by 2060, according to the National Institute on Aging.
While good health is key to independence and productivity later in life, a staggering 93% of older Americans have at least one chronic condition — and nearly 80% suffer from two or more.
'These insights may facilitate the development of targeted interventions for ageing and age-related diseases, paving the way to improve the health of older adults,' the study authors concluded.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

China's clinical trial ecosystem takes centre stage in Suzhou this September
China's clinical trial ecosystem takes centre stage in Suzhou this September

Yahoo

timean hour ago

  • Yahoo

China's clinical trial ecosystem takes centre stage in Suzhou this September

China's rapid emergence as a global clinical trials powerhouse will be in sharp focus this September as leading voices from the biopharma and healthcare sectors convene in Suzhou for the launch of Outsourcing in Clinical Trials China and Clinical Trial Supply China. Held over two days on 3-4 September 2025, the dual event brings together senior executives, regulators, and innovators across R&D, clinical operations, outsourcing, and supply chain to examine the evolving landscape of clinical development in China - arguably the world's most dynamic biopharma market. Strategic inflection point China's clinical trials sector has undergone significant structural transformation over the past five years, driven by a combination of regulatory shifts, capital inflows into biotech, and a shift toward more decentralised, patient-centric trial models. According to GlobalData analysis, China now surpasses the US for annual number of clinical trials. Yet as the ecosystem expands, so too does its complexity - particularly in relation to cross-border compliance, data protection, and clinical logistics. This new industry event marks a pivotal moment, featuring an opening keynote panel on 'The Evolving Clinical Trial Landscape in China: Challenges & Opportunities,' alongside in-depth discussions on artificial intelligence in drug discovery, clinical supply chain management, and geopolitical risk. Sessions will span core operational challenges - including site selection, enhancing collaboration in outsourcing, comparator sourcing, cold chain logistics, and vendor management - as well as broader questions on global collaboration, clinical trial harmonisation, and China's biotech ambitions. The program includes a panel on 'The Rise of Chinese Biotech: A Competitive Challenge for US Companies and Investors,' reflecting growing interest in China's ability to scale R&D innovation, supported by state policy and venture capital. While China continues to make strides in drug discovery and innovation, integration into the global clinical development ecosystem remains uneven. Concerns around IP protection, regulatory uncertainty, and data localisation persist, particularly for international sponsors managing multi-country trials. Speakers from IDA Ireland, Singapore's Agency for Science, Technology and Research, and the US Maryland China Center will participate in a cross-border panel addressing the impact of China's biotech boom on global trials. On 4 September, delegates will have the opportunity to participate in a curated site visit to Biobay, the national biomedical innovation zone located in Suzhou Industrial Park. The tour includes direct engagement with local biotech executives and exposure to platform technologies shaping the next wave of drug development. Confirmed speakers include: Li Zeng, CEO, Jing Medicine Summer Xia, CEO, Trial-Data Medicine Vincent Zang, Senior Director, Clinical Trial Operation, Innovent Bio Angela Yu, Head of Outsourcing, East China Pharm Shen Xiao, CMO, Alebund Siwei Li, Director, Drug Metabolism and Pharmacokinetics, Degron Therapeutics Xiaoyu Deng, Founder, MDCE Medical Megan Qin, Head of Medical Device Clinical Excellence Working Group, CMAC Xiaoyu Deng, Founder, MDCE Medical Claire Qin, Chief Strategy Officer, Intelligen AI Min Geng, Head of Supply Chain, Shanghai Pharma Fiona Barry, Editor in Chief & Director, Globaldata Healthcare Shelly Xie,Associate Director, Clinical & QC Management,Eli Lilly Jinna Qin, President, China Association for Vaccines Daniel Gao, President, ISPE Supply Chain Committee Xiaomei Wang, VP of Clinical Trial Operation, Key Therapharma Yugang Ju, Head of Clinical Operation, Insilico Medicine Quancheng Chen, Agency for Science, Technology and Research, Singapore Chester Xiao, Head of Life Science Industry, IDA Ireland Vikki Wang, Head of China Center, U.S. Maryland China Center View the full list of speakers and the complete conference agenda here. Don't miss this exclusive opportunity to connect with industry leaders, gain actionable insights, and stay ahead in the rapidly evolving clinical trials landscape in China. Join the Outsourcing in Clinical Trials China & Clinical Trial Supply China, happening 3-4 September at the Renaissance Suzhou Hotel. Register here: "China's clinical trial ecosystem takes centre stage in Suzhou this September" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

US Intelligence Flight Detected on China's Doorstep
US Intelligence Flight Detected on China's Doorstep

Newsweek

time3 hours ago

  • Newsweek

US Intelligence Flight Detected on China's Doorstep

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A United States military aircraft designed to gather radar signals was detected flying deep in the contested South China Sea on Tuesday, publicly available flight data showed. Newsweek reached out to the Chinese Defense Ministry and U.S. Pacific Air Forces via email for comment outside of office hours. Why It Matters The Pentagon typically does not disclose specifics about its military operations, but a U.S. Air Force fact sheet says the Combat Sent collects "strategic electronic reconnaissance information" for decision makers in the U.S. military chain of command. "Locating and identifying foreign military land, naval and airborne radar signals, the Combat Sent collects and minutely examines each system, providing strategic analysis for warfighters," the Air Force said, in a description of the platform's role in developing effective anti-radar countermeasures such as jamming. What To Know The RC-135U, also known as the Combat Sent, probed the waters around the disputed Spratly and Paracel islands in a 10-hour flight from a major military hub in southwestern Japan, according to self-reported geodata recorded by the website Flightradar24. The August 6 flight was first spotted by open-source intelligence analyst MeNMyRC1, a former RC-135 crew member and signals intelligence platform specialist. They said it was unusual for U.S. spy flights to be seen so far south in the South China Sea, while noting that the area often lacks enough ground receivers to pick up aircraft tracks. The Combat Sent, which was deployed in late June from the continental United States to Kadena Air Base on the Japanese island of Okinawa, flew its latest sortie just after 6 a.m. universal coordinated time, or UTC, according to Flightradar24. It did not land until after 4 p.m. UTC the same day. An RC-135 V/W RIVET JOINT takes off from Offutt Air Force Base in Nebraska on March 31, 2025. An RC-135 V/W RIVET JOINT takes off from Offutt Air Force Base in Nebraska on March 31, 2025. Chad Watkins/U.S. Air Force Flight records showed the Combat Sent has been deployed on suspected electronic intelligence-gathering flights at least 11 times since July 1, probing contested areas including just south of the North Korean border as well as near China's southernmost province of Hainan, home to one of the Chinese navy's aircraft carriers stationed in the South China Sea. The Air Force says the Combat Sent aircrew includes "a minimum of 10 electronic warfare officers…and six or more mission area specialists." The plane has a fuel range of over 4,500 miles and an operational ceiling higher than 35,000 feet. The U.S. military has two Combat Sent platforms in operation. They first flew in the mid-1960s and are expected to remain in service until the 2040s. Beijing-based think tank the South China Sea Strategic Situation Probing Initiative wrote on X that it had tracked 48 sorties by U.S. spy planes over the South China Sea in July alone, four of which were RC-135s. China claims sovereignty over the Spratly archipelago off the west coast of the Philippines and has controlled the Paracel group east of Vietnam since the mid-1970s. In both sets of disputed islands, China has artificially expanded shoals and reclaimed reefs to create large military bases housing radars, barracks and airfields. What People Are Saying Chinese Foreign Ministry spokesperson Mao Ning told reporters on February 9: "US aircraft and warships frequently conduct close-in reconnaissance around China, which seriously threatens China's national security and undermines regional peace and stability. What Happens Next Both the U.S. and Chinese militaries are expected to continue deploying surveillance planes in the western Pacific.

Don't Let Communist China Poison Our Path to a Healthier America
Don't Let Communist China Poison Our Path to a Healthier America

Epoch Times

time4 hours ago

  • Epoch Times

Don't Let Communist China Poison Our Path to a Healthier America

Communist China isn't just trying to compete with the United States in pharmaceuticals—it's trying to overtake us. Backed by massive state investment and regulatory shortcuts, China has quickly emerged as a global powerhouse in drug development. In 2024 alone, China conducted more clinical trials than the United States and is now developing almost as many new drugs as America is. While U.S. innovators are bogged down by bureaucratic red tape, Chinese companies are racing ahead, often with far less oversight. China's rise isn't just about innovation—it's about infiltration. Increasingly, unapproved and unregulated Chinese-made compounds —including weight-loss drugs—make their way into the United States through online compounding pharmacies, social media sellers, and sketchy e-commerce platforms. Many of these products evade scrutiny by the U.S. Food and Drug Administration; yet they're being consumed by millions of Americans who assume what they're taking has been properly vetted. This is more than a public health risk—it's a national security threat. The Chinese regime is exploiting the United States' regulatory gaps and consumer vulnerabilities, flooding the market with untested therapies while positioning itself as the world's next pharmaceutical superpower. Meanwhile, U.S. manufacturers face stricter standards and longer approval timelines, creating an uneven playing field that punishes American compliance and rewards Chinese circumvention. Take knock-off weight-loss treatments. More than 9 out of 10 Americans worry about what's in these drugs and where they come from. Indeed, such compounded medicines aren't coming from your trusted neighborhood pharmacy. They're being manufactured with ingredients often sourced from China, with little to no transparency about what's actually in them. No FDA approval. No clinical trials. Just chemical cocktails dressed up to look like legitimate treatments. The FDA has already issued strong public warnings about the risks of these unapproved GLP-1 drugs being used for weight loss. In fact, the agency has gone out of its way to warn doctors, patients, and compounders that these products are neither tested nor safe. But rather than heed those warnings, some of these compounders are thumbing their nose at federal regulators, ignoring the law, and continuing to crank out untested drugs. Fortunately, Congress is paying attention. Last month, a group of 80 lawmakers sent a letter to the Trump administration demanding a crackdown on these foreign-made, non-FDA-approved knock-off drugs. They rightly warned that this shadow market not only puts Americans at risk—it threatens to destabilize our entire pharmaceutical system. This isn't just about health. It's about sovereignty and security. While American companies play by the rules—undergo rigorous testing, FDA approval, and years of research and development—Chinese labs and compounders cut corners, flood our market, and profit off Americans trying to live healthy lives. Allowing compounders to churn out copycat GLP-1s creates a 'Wild West' in our supply chain, outsourcing critical medicines and bolstering a Chinese pharmaceutical industry that aims for global dominance. That undercuts U.S. manufacturing jobs and cedes strategic advantage to a geopolitical rival. The United States can't afford to sleepwalk into pharmaceutical dependence. When unregulated drugs from overseas flood our market and compounders openly defy FDA warnings, it sends a dangerous message: that we're willing to outsource public health to geopolitical rivals. China understands the stakes—that's why it's investing billions to become the world's medicine cabinet. Let's recognize China's pharmaceutical surge for what it is: a deliberate strategy to dominate the world's medicine supply. If we allow rogue compounders to undercut FDA standards and flood the market with unvetted weight-loss therapies, we're not just enabling a regulatory loophole—we're accelerating a dangerous shift in global pharmaceutical power. America must decide: do we want to hand our medicine supply over to a geopolitical rival that plays by a different set of rules? The more we tolerate this gray market, the more we erode the integrity of our pharmaceutical system and outsource our health security to a strategic competitor. We must make it absolutely clear that the United States is not open for business to unapproved drugs, whether for weight-loss or any other condition, especially ones built on foreign shortcuts and bad faith.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store